LV-CAG-Venus-T2A-AkaLuc

What it means: CAG is the CMV enhancer / chicken beta-actin hybrid promoter, a very strong, ubiquitous promoter built from the CMV enhancer, the chicken beta-actin promoter and a rabbit beta-globin splice acceptor.

Why it matters:

• The promoter sets where and how strongly the cassette is expressed after transduction.
• CAG drives robust expression in most mammalian cell types and in vivo.
• Promoter choice also affects how quickly expression appears and whether it persists after weeks in culture or in vivo.

How to interpret here: in LV-CAG-Venus-T2A-AkaLuc, CAG drives Venus and AkaLuc, so expect the expression pattern described above in transduced cells.

Tip: when comparing constructs, keep the promoter constant — differences between CAG and another promoter can be larger than the effect of the transgene itself.

What it means: this vector co-expresses Venus and AkaLuc. Venus is a fluorescent protein reporter; transduced cells can be identified by fluorescence microscopy or flow cytometry. AkaLuc is a luciferase reporter that produces light in the presence of its substrate, enabling sensitive bioluminescence readouts in vitro and in vivo.

Why it matters:

• Venus and AkaLuc combine a fluorescent reporter with a luciferase, giving one readout for microscopy or sorting and one for luminescence.
• Match filters or lasers to the fluorescent component only; the luciferase component needs its substrate instead.
• Having both lets the same cells be tracked in culture by fluorescence and in vivo by luminescence.

How to interpret here: transduced cells express Venus and AkaLuc; use the fluorescent component for cell-level work and the luciferase component for bulk or in vivo signal.

Tip: validate the fluorescent and luciferase components separately the first time — a strong fluorescent signal does not guarantee the luciferase arm is working.

What it means: Constitutive — expression is continuous and not dependent on an inducer or recombinase.

Why it matters:

• No additional reagent or driver line is needed; expression begins after integration and continues in daughter cells.
• No inducer, recombinase, driver line or partner construct is needed, which keeps the experiment simple.
• The trade-off is that expression cannot be switched off or timed, so it continues from integration onward in every transduced cell.

How to interpret here: LV-CAG-Venus-T2A-AkaLuc expresses its cassette continuously from the CAG promoter as soon as it has integrated.

Tip: compare against a control vector with the same backbone, promoter and selection marker rather than against untransduced cells, so transduction and selection effects can be separated from the cassette effect; ask us if a matching control is not listed.

What it means: None — no antibiotic resistance gene is included.

Why it matters:

• Without a resistance gene there is no drug step, so no stable pool can be enriched by selection; identify transduced cells by the Venus and AkaLuc reporter, by FACS or by a functional readout.
• Leaving the marker out keeps the cassette smaller and avoids occupying a resistance gene that another construct in the same cells may need.
• It also means the transduced and untransduced fractions stay mixed unless they are physically sorted.

How to interpret here: the selection marker for this vector is None.

Tip: sort on the reporter to obtain a uniform population, and record the transduced fraction so downstream results can be corrected for it.

What it means: >1E+9 TU/mL is the functional titer in transducing units (TU) per mL — the number of particles that actually deliver and express the cassette, not the physical particle count.

Why it matters:

• Functional titer is what determines the multiplicity of infection (MOI) you can reach with a given volume.
• The value is stated as a minimum (>1E+9 TU/mL), so treat it as a floor when planning volumes rather than as an exact content figure.
• Functional titers are assay-dependent, so compare titers between vendors only when the titration method is the same.

How to interpret here: calculate MOI from >1E+9 TU/mL and your cell number; optimize MOI per cell type, since transduction efficiency differs between lines and primary cells.

Tip: keep the vector cold during dilution and avoid vortexing — titer loss from repeated freeze-thaw or rough handling is the most common reason a >1E+9 TU/mL stock underperforms.

What it means: BSL-2 is the biosafety containment level required for handling this lentiviral vector.

Why it matters:

• BSL-2 work requires a certified biosafety cabinet, appropriate PPE and decontamination of all waste and surfaces.
• Institutional biosafety approval is usually required before lentiviral work begins, and transfer between labs follows the same containment rules.
• Transduced cells and used media remain BSL-2 material until decontaminated.

How to interpret here: handle LV-CAG-Venus-T2A-AkaLuc under BSL-2 practices throughout storage, thawing, transduction and disposal.

Tip: check whether your institution requires enhanced BSL-2 practices for lentiviral vectors carrying particular transgenes; this varies between institutions.